Spyre Therapeutics (NASDAQ:SYRE) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Spyre Therapeutics (NASDAQ:SYRE) from a hold rating to a sell rating in a report released on Saturday.

Other equities research analysts have also recently issued research reports about the stock. Wells Fargo & Company increased their price target on shares of Spyre Therapeutics from $40.00 to $50.00 and gave the company an “overweight” rating in a report on Friday. Citigroup initiated coverage on Spyre Therapeutics in a research note on Wednesday, December 17th. They set a “buy” rating and a $64.00 target price on the stock. Mizuho raised Spyre Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. BTIG Research reaffirmed a “buy” rating and set a $70.00 price target on shares of Spyre Therapeutics in a report on Friday. Finally, JonesTrading raised Spyre Therapeutics from a “hold” rating to a “buy” rating and set a $64.00 price objective on the stock in a research report on Monday, December 1st. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Spyre Therapeutics has an average rating of “Buy” and an average price target of $53.44.

Spyre Therapeutics Price Performance

Shares of NASDAQ:SYRE opened at $43.21 on Friday. The business has a fifty day moving average price of $33.40 and a 200-day moving average price of $25.35. The company has a market capitalization of $3.35 billion, a PE ratio of -20.77 and a beta of 3.15. Spyre Therapeutics has a 1-year low of $10.91 and a 1-year high of $43.56.

Spyre Therapeutics (NASDAQ:SYRE) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.04). On average, sell-side analysts anticipate that Spyre Therapeutics will post -4.46 earnings per share for the current fiscal year.

Insider Transactions at Spyre Therapeutics

In other Spyre Therapeutics news, CEO Cameron Turtle sold 15,000 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $32.80, for a total transaction of $492,000.00. Following the completion of the sale, the chief executive officer directly owned 657,540 shares in the company, valued at $21,567,312. The trade was a 2.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold 45,000 shares of company stock valued at $1,387,500 over the last 90 days. Company insiders own 15.43% of the company’s stock.

Hedge Funds Weigh In On Spyre Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in SYRE. CWM LLC grew its position in Spyre Therapeutics by 357.8% during the second quarter. CWM LLC now owns 1,712 shares of the company’s stock valued at $26,000 after buying an additional 1,338 shares during the period. Persistent Asset Partners Ltd bought a new stake in shares of Spyre Therapeutics during the 4th quarter valued at $74,000. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Spyre Therapeutics by 61.5% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,770 shares of the company’s stock valued at $124,000 after acquiring an additional 1,435 shares during the period. AlphaQuest LLC increased its stake in shares of Spyre Therapeutics by 30.8% in the 2nd quarter. AlphaQuest LLC now owns 4,174 shares of the company’s stock worth $62,000 after purchasing an additional 983 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its holdings in Spyre Therapeutics by 2,881.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 4,234 shares of the company’s stock worth $71,000 after purchasing an additional 4,092 shares during the period. Hedge funds and other institutional investors own 80.39% of the company’s stock.

Key Spyre Therapeutics News

Here are the key news stories impacting Spyre Therapeutics this week:

• Positive Sentiment: BTIG Research reaffirmed its “buy” rating and kept a $70 price target (roughly +62% upside vs. current levels), signaling strong buy-side conviction from a sell-side firm. BTIG Reaffirms Buy, $70 PT
• Positive Sentiment: Wells Fargo raised its price target to $50 and assigned an “overweight” rating, providing additional analyst support that likely helped lift the stock. Wells Fargo Raises PT to $50
• Positive Sentiment: Spyre reported a strong cash position — $757M in cash, equivalents and marketable securities as of 12/31/25 — and said that runway is expected into H2 2028, reducing near-term financing risk. The company also completed an offering in Oct 2025 and added a Chief Commercial Officer. Q4 & Corporate Update
• Positive Sentiment: Management reiterated an aggressive 2026 clinical cadence: up to six proof-of-concept readouts across the SKYLINE and SKYWAY Phase 2 programs (including Part A readouts starting in Q2 and multiple basket-study sub-readouts later in the year), which creates several near-term clinical catalysts. Clinical Readouts and Timeline
• Neutral Sentiment: Spyre announced presentations at the 21st ECCO Congress showcasing SPY003’s differentiated profile and preclinical combo data — supportive from a scientific/visibility standpoint but not an immediate financial catalyst. ECCO Presentations
• Negative Sentiment: Spyre missed the quarterly EPS consensus (reported -$0.70 vs. est. -$0.66), a modest miss that may temper sentiment for investors focused on near-term financials. Earnings Release

About Spyre Therapeutics

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.